Iram · Nature 2022 · Preclinical animal interventional and in vitro cell study · n=?

Young CSF restores oligodendrogenesis and memory in aged mice via Fgf17.

Cited 208 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical animal and in vitro laboratory experiment.

PubMed 35545674 · doi:10.1038/s41586-022-04722-0 · record verified 2026-08-26

What was done

Infused young cerebrospinal fluid (CSF) into aged mouse brains and assessed memory function. Conducted unbiased transcriptomic analysis of the hippocampus and evaluated oligodendrocyte progenitor cell (OPC) proliferation and differentiation in aged mice and primary OPC cultures. Used SLAMseq nascent mRNA labeling to identify downstream transcription factors. Screened CSF factors and tested direct infusion of fibroblast growth factor 17 (Fgf17) in aged mice and Fgf17 blockade in young mice.

What was found

The abstract reports qualitative directional findings without numerical values. Young CSF improved memory function in aged mice and stimulated hippocampal OPC proliferation and differentiation. Transcriptomic profiling identified oligodendrocytes as the most responsive cell type. SRF expression decreased in aged hippocampal OPCs and was restored by young CSF. Fgf17 infusion was sufficient to induce OPC proliferation and long-term memory consolidation in aged mice, whereas Fgf17 blockade impaired cognition in young mice.

Why it matters

Demonstrates that young CSF can rejuvenate the aged brain microenvironment and identifies Fgf17-mediated oligodendrogenesis as a potential therapeutic pathway for age-related cognitive decline.

Limits

Conducted entirely in mouse models and cell cultures; relevance to human cognitive aging remains unproven. The abstract reports no sample sizes, effect sizes, or statistical metrics. Potential off-target effects and long-term safety of CSF or Fgf17 administration were not reported.

Cited by